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An in vitro assessment of 
liposomal topotecan simulating 
metronomic chemotherapy in 
combination with radiation in 
tumor-endothelial spheroids
Amar Jyoti1, Kyle D. Fugit1, Pallavi Sethi1, Ronald C. McGarry2, Bradley D. Anderson1 & 
Meenakshi Upreti1
Low dose metronomic chemotherapy (LDMC) refers to prolonged administration of low dose 
chemotherapy designed to minimize toxicity and target the tumor endothelium, causing tumor 
growth inhibition. Topotecan (TPT) when administered at its maximum tolerated dose (MTD) is often 
associated with systemic hematological toxicities. Liposomal encapsulation of TPT enhances efficacy 
by shielding it from systemic clearance, allowing greater uptake and extended tissue exposure 
in tumors. Extended release of TPT from liposomal formulations also has the potential to mimic 
metronomic therapies with fewer treatments. Here we investigate potential toxicities of equivalent 
doses of free and actively loaded liposomal TPT (LTPT) and compare them to a fractionated low 
dose regimen of free TPT in tumor-endothelial spheroids (TES) with/without radiation exposure 
for a prolonged period of 10 days. Using confocal microscopy, TPT fluorescence was monitored to 
determine the accumulation of drug within TES. These studies showed TES, being more reflective 
of the in vivo tumor microenvironment, were more sensitive to LTPT in comparison to free TPT 
with radiation. More importantly, the response of TES to low-dose metronomic TPT with radiation 
was comparable to similar treatment with LTPT. This TES study suggests nanoparticle formulations 
designed for extended release of drug can simulate LDMC in vivo.
Traditional chemotherapeutic regimens incorporate the maximum tolerated dose (MTD)1 resulting in 
systemic toxicity. These toxicities mandate rest periods between cycles of therapy and result in re-growth 
of drug-resistant tumor cells and growth of more malignant tumors with no therapeutic response2. Low 
dose metronomic chemotherapy (LDMC) designed to minimize toxicity, functions by targeting the 
tumor microenvironment, particularly the endothelial cells, by frequent, fractionated doses of MTD. The 
potential need for frequent administrations has not allowed LDMC to advance beyond investigational 
applications. Topotecan (TPT), a water soluble camptothecin with topoisomerase I inhibitory activity 
when administered at its maximum tolerated dose (MTD) is often associated with systemic hematolog-
ical toxicities. Metronomic oral TPT has been reported to have beneficial outcomes in clinical trials3,4 
and preclinical tumor models5,6 of various cancer types. Liposomal encapsulation of TPT enhances its 
efficacy by shielding it from systemic clearance, allowing greater uptake and extended tissue exposure in 
solid tumors7,8. Extended release of TPT from liposomal formulations also has the potential to mimic 
metronomic therapies with fewer treatments. Endothelial cells in tumors are typically more sensitive than 
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other tumor cells to prolonged LDMC9. Targeting these endothelial cells blocks tumor angiogenesis and 
eventually inhibits tumor growth10,11. However, similar to other anticancer therapies, inherent resistance 
to LDMC is also frequent12. Existing pre-clinical tumor cell models have yet to incorporate the variables 
of angiogenesis and intercellular heterogeneity of the tumor microenvironment. Furthermore, evaluating 
LDMC before extending it to preclinical animal models and clinical settings has also been difficult due 
to the above mentioned variables13.
The inadequacies of the tumor microenvironment in most in vitro tumor cell models has also made 
the design of drug delivery systems with optimal drug release rates challenging. The chronically aber-
rant vascular pathophysiology of developing tumors results in a leaky vasculature and poor lymphatic 
drainage14 that allows nanosized drug carriers like liposomes to preferentially accumulate. The enhanced 
permeability and retention (EPR) effect can result in 10–50 fold higher concentration of nanoparticles 
in tumors than in normal tissue15. Furthermore, sustained release of active drug from these nanoformu-
lations simulates the action of metronomic therapy16. However, accumulation of drug-loaded liposomes 
in tumors as a consequence of the EPR effect may not lead to optimal free drug concentrations at the 
tumor site, and thus may not be a sufficient indicator of therapeutic efficacy17. Traditional 2D monolayer 
cell culture systems do not exemplify the complexity of the tumor and its microenvironment and are also 
not optimal for assessing nanoparticle efficacy18. Therefore, an in vitro tumor model that is amenable to 
monitoring nanoparticle penetration, drug release, and their subsequent effects on tumor cell viability 
and/or tumor growth is needed. The 3D system of tumor and endothelial cells co-cultured in ‘hang-
ing drops’ recreates aspects of the tumor microenvironment, offering a simple yet potentially powerful 
in vitro tumor model to study therapeutic response. These avascular multicellular TES recreate the gradi-
ent of hypoxia, pH and interstitial pressure that results in the inner necrotic and the outer proliferating 
layer of cells similar to solid tumors in vivo19,20. The co-culture of different cell types in 3D also facilitates 
the inter-cellular crosstalk leading to the formation of an extracellular matrix known to influence the 
therapeutic response in cancer21. Liposomal formulations of TPT enhance the anticancer efficacy of TPT 
and significantly reduce tumor growth7,8 but reasons behind this outcome are not fully understood. In 
the current study, a TES model of triple negative breast cancer (TNBC) was used to investigate whether 
the extended release and drug penetration from liposomal TPT provided similar cytotoxicity as metro-
nomic dosing.
Radiation alters the adjacent tumor microenvironment often with consequences for cancer cells 
beyond the direct effects of the radiation itself 22. Radiation therapy with concomitant or delayed chemo-
therapy is given to almost 70% of the patients with cancer. TPT has also been shown to induce radio-
sensitization upon prior or concurrent treatment with radiation23. Therefore, this study investigates the 
combined effect of a clinically relevant dose of radiation (3 Gy) in conjunction with free or liposomal on 
avascular tumor-endothelial spheroids over an extended period of 10 days.
Results
Extended release kinetics of LTPT in physiological buffer and culture medium. Simulating 
metronomic dosing requires sustained release of TPT from liposomes under study conditions. Using a 
spectroscopic method developed in previous work to monitor the release kinetics of LTPT in aqueous 
buffer and biological fluids24, TPT release was monitored in cell culture medium to determine if LTPT 
formulations provided sustained release in TES media. Release kinetics of three different LTPT suspen-
sions (11, 17 and 23 μ M total suspension TPT) in TES media are shown in Fig. 1 and were compared 
to release from LTPT (12 μ M total suspension TPT) in pH 7.4 PBS. While slightly greater in cell culture 
media than in PBS, TPT release was still sustained over the 31 hr period release was monitored. This 
time frame is relevant when considering TESs treated with LTPT were washed after 24 hr of exposure 
to the formulation.
Higher intrinsic sensitivity of endothelial cells to TPT alone and in combination with radiation 
than tumor cells. Cellular viability was determined by MTT assay in monolayer cell cultures of 4T1 
mammary breast carcinoma and 2H11 endothelial cell lines treated with increasing concentrations of 
TPT. Comparing Fig.  2A,B clearly demonstrates that endothelial cells are more sensitive to TPT treat-
ment. The half maximal inhibitory concentrations (IC50) of TPT were 130 nM for endothelial cells and 
630 nM for tumor cells. Combined treatment of TPT in conjunction with radiation further sensitized 
both the tumor and endothelial cells in the 72 hour MTT assay. An approximate 10-fold decrease was 
evident in the values of the IC50 of the tumor cells from 630 nM to 75 nM and endothelial cells from 130 
to 17 nM, respectively, when TPT treatment was combined with 3 Gy of radiation after 6 hours.
Ionizing radiation triggers a myriad of responses in cells, including apoptosis, necrosis, stress-induced 
premature senescence (SIPS) and autophagy. Most of these responses result in loss of colony-forming 
ability that may be assessed in the clonogenic survival assay25. Clonogenic studies to understand the 
effects of TPT and radiation exposure of 3 Gy in tumor and endothelial cell lines further indicated that 
TPT concentrations at one-half and one-fourth of the IC50 were more effective in inhibiting survival of 
both cell types (Fig. 2C,D).
Tumor-endothelial cell spheroids (TES): an in vitro model to assess drug penetration and 
accumulation. Tumors in vivo are not merely aggregates of cancer cells but are representative of 
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structurally and functionally deregulated organs with a 3D tissue architecture contributed by multi-
ple cell types and the extracellular matrix26,27. Gravity-enforced self-assembly generates multicellular 
scaffold-free aggregates in a self-contained microenvironment28. The penetration of free TPT was assessed 
Figure 1. Extravesicular TPT concentrations versus time in LTPT suspensions at various dilutions in 
PBS or culture media at pH 7.4 and 37 °C. Release profile of LTPT formulations in PBS buffer and spheroid 
culture media at pH 7.4 and 37 °C. Graph represents the extravesicular TPT concentration calculated over 
time in the TES culture media and PBS buffer. The extravesicular TPT was quantified by monitoring TPT 
fluorescence at ex. and em. wavelengths of 410 and 550 nm, respectively. The lines are trendlines for the four 
different release experiments.
Figure 2. Endothelial cells are more sensitive to low concentrations of TPT alone and in combination 
with radiation in comparison to tumor cells. Effect of TPT treatment on the viability of tumor (A) and 
endothelial cells (B) was assessed with or without radiation (3 Gy) exposure in a 72h MTT assay. IC50 values 
obtained from the MTT assay indicate that X-ray irradiation post TPT treatment considerably decreases 
the viability of both tumor and endothelial cells. Long term survival studies further validate the impact of 
radiation (3y) on tumor and endothelial cell colony formation with and without TPT at ½ or ¼ of the IC50 
concentrations. For the survival assay, cells were exposed to drug and/or radiation and then grown in drug-
free medium for 10–14 days. Colonies (> 50 cells) were stained with crystal violet and counted (Materials 
and Methods). Data represent means ± SD (n = 3). Significant changes were recorded as **p < 0.01; 
*p < 0.05.
www.nature.com/scientificreports/
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at excitation wavelength of 410 nm in tumor cell only and tumor-endothelial cell spheroids (TES) incu-
bated in 2.5 μ M TPT for 6 hours by confocal fluorescence microscopy. The drug uptake within 6 hours 
of incubation was noticeably higher in the tumor cell only spheroids in comparison to tumor-endothelial 
cell spheroids (TES) (Fig.  3A). Scanning electron microscopy and H & E staining revealed that while 
tumor cells remain as aggregates and fail to form intact spheroids, the tumor and endothelial cells in the 
TES developed an integrated and compact architecture with indications of ECM formation (Fig. 3B,C). 
Immunohistochemical (IHC) studies indicated that the presence of both tumor and endothelial cells in 
3-dimensions causes the production of extracellular matrix proteins like fibronectin and collagen. These 
factors may be responsible for the integrated tissue-like morphology and greatly limited penetration of 
TPT (Fig. 3D). The presence of extracellular matrix (ECM) has been reported to affect the penetration 
of therapeutic agents in solid tumors29 as observed in the present study. The tumor cell only spheroids 
exist as unattached cell aggregates and are either washed out during the IHC procedures or have minimal 
expression of ECM proteins (data not shown).
Figure 3. Tissue-like integrated morphology and development of extracellular matrix prevents 
penetration of TPT in the TES. (A) Tumor cell only and tumor-endothelial cell (TES) spheroids were 
incubated in 2.5 μ M TPT for 6 hours and extent of uptake was assessed using fluorescent confocal imaging. 
Efficient uptake of TPT imaged at excitation wavelength 410 nm was observed in tumor cell spheroids. 
There was minimal penetration of the fluorescent TPT (green). Scanning electron micrographs (B), histology 
(C) and immunostaining for ECM proteins (D) like collagen and fibronectin indicate the compactness as 
well as the presence of ECM in the TES.
www.nature.com/scientificreports/
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Higher TES accumulation and penetration of TPT from liposomal formulations. The TES 
were incubated in 5 μ M of free or LTPT with and without radiation exposure (3 Gy) for 24 hours. The 
media was replaced and the spheroids were assessed for accumulation and penetration of TPT at day 10. 
Sustained release of drug from liposomes and changes caused by radiation are expected to occur over 
a period of time in vivo. Therefore, drug accumulation and cytotoxicity in TES was assessed at 10 days 
post-treatment for optimal results. Maximum intensity projections of a stack of 24 confocal images at a 
5 μ m step size of each TES were portioned into 5 concentric zones as shown in Fig. 4A. The integrated 
intensity normalized to surface area of each respective zone in every treatment group was represented in 
Fig. 4C. The quantification of TPT accumulation based on the fluorescence intensity in each zone of the 
TES 10 days after treatment indicates significantly higher accumulation in zone-1 and zone -2 of TES 
incubated in LTPT following radiation exposure (Fig. 4C). Figure 4B is a representative image showing 
a confocal image of a TES in tile mode, with accumulation and penetration of the drug in the 24 optical 
sections at different z-levels. Heat maps depicting the distribution of TPT within the TES in different 
treatment groups further indicate that the drug penetration was more efficient in TES incubated in LTPT 
and exposed to a 3 Gy dose of radiation (see Fig. 4D). Absence of the outer zones (3, 4 and 5) reflects a 
Figure 4. Liposomal TPT formulation facilitates penetration of TPT in TES over an extended period 
of 10 days. Comparisons of intra-spheroidal TPT uptake in TES when incubated in the presence of either 
free or liposomally entrapped TPT for 24 hours with and without radiation exposure of 3 Gy at day 10 
post-treatment. (A) Confocal TES images were partitioned into 5 concentric zones for quantification of TPT 
accumulation (Zones (1–5). (B) Representative confocal images after treatment of 24 optical slices (i.e. each 
z-stack image) taken every 5 μ m from the center to bottom of the intact TES. The top left image in each tile 
is a 3D reconstruction of the stack of 24 confocal optical sections. (C) Quantification of TPT accumulation 
based on the integrated TPT fluorescence intensity (integrated intensity normalized to surface area in each 
zone to avoid bias) in each zone of the TES after treatment with liposomal TPT. (D) Heat map of fluorescent 
confocal images showing the intracellular accumulation of TPT across the y and z-axis of TES. Each image 
represents averages of fluorescence intensity of 4 TES within the same treatment group.
www.nature.com/scientificreports/
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decrease in TES size. Penetration of TPT to the inner layers of the TES is indicative of the higher level 
of cytotoxicity resulting from the combined treatment of LTPT and radiation in comparison to the other 
treatment groups.
Free and liposomal formulations of TPT at concentrations of 5 μ M were also prepared in the pH 
7.4 culture medium used to grow the TES. Six hours later, treated TES were imaged by confocal flo-
rescence microscopy at an excitation wavelength of 410 nm. The fluorescence intensity of the culture 
medium with liposomally entrapped TPT (LTPT) was exceptionally low in comparison to free TPT 
(Supplementary Figure. 1). Similar images were obtained at 24 hours, the time point when the TES 
medium was replaced with fresh medium (data not shown). These results, in addition to those in Fig. 4, 
suggest that TPT-loaded liposomes accumulate in the TES within 24 hours, followed by extended release 
of the drug during the 10 day studies.
Low concentrations of LTPT and radiation enhance TES cytotoxicity when assessed over 
a prolonged period of time. The anti-tumor effects of radiation and TPT occur via their impact 
on the tumor microenvironment, particularly the endothelial cells30. The response of the tumor/tumor 
microenvironment to combined therapy using liposomally-entrapped TPT and radiation was assessed 
in 3D co-cultures of tumor and endothelial cells (TES) by incubating at a TPT concentration of 250 nM 
followed by exposure to a clinically relevant dose of radiation (3 Gy). The selected TPT concentration 
was 2-fold higher than the half maximal inhibitory concentration (IC50) for endothelial cells and 3-fold 
less than the IC50 for the tumor cells (Fig. 2). The effect of free and LTPT with and without radiation 
(3 Gy) was observed on day 10 by assessing the size, GFP expression of 4T1 tumor cells and extent of 
cell damage by Propidium Iodide (PI) staining of TES (Fig. 5A,B).
Figure 5. Enhanced cytotoxicity in TES upon combined treatment with a low concentration of 
liposomal TPT (LTPT) and radiation. (A) Representative confocal images of GFP expressing tumor cells 
and PI uptake elucidating the effect of free and entrapped TPT treatment (250 nM) with and without 
radiation (3 Gy). Each treatment was expected to reduce the overall fluorescence of GFP expressing 4T1 
tumor cells, increase the accumulation of the PI stain and decrease the size of TES. These effects are 
indicative of the level of cytotoxicity conferred by each treatment. Increase in PI staining, decrease in 
spheroid size and GFP expression were observed in TES treated with LTPT followed by radiation exposure, 
indicating higher cytotoxicity. (B) Spheroid size and the ratio of PI/GFP intensity were evaluated using 
ImageJ software. (n = 12 TES for spheroid size per treatment and n = 4 TES for PI/GFP ratio) **P < 0.01.
www.nature.com/scientificreports/
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PI is a fluorescent nuclear and chromosome counterstain that is impermeant to live cells, making it a 
useful indicator of dead cells within a population. The emission maximum for the dye bound to DNA is 
617 nm and therefore it fluoresces red31. TES subjected to radiation exposure (3 Gy) alone underwent a 
decrease in size at day 10 with a moderate increase in PI staining. While staining with PI was significant 
in TES that were incubated in LTPT with and without radiation exposure (3 Gy) the combined effects of 
a decrease in size and cell damage as observed by PI staining were significantly higher in TES that were 
subject to incubation with LTPT in conjunction with radiation (Fig. 5A). High throughput evaluations 
of spheroid size and ImageJ-based determinations of decrease in the fluorescence intensity of green fluo-
rescent (GFP) expressing 4T1 tumor cells (green) and increase of PI staining in the TES further validate 
the enhanced cytotoxicity induced by LTPT in conjunction with radiation (Fig. 5B).
Extended release of TPT from liposomes mimics the low dose metronomic dosing effect in 
TES. Metronomic chemotherapy targets the tumor microenvironment, particularly the endothelial 
cells which are more sensitive to lower and sustained doses of drugs than the tumor cells. Inhibiting 
tumor endothelial cells disrupts the normal interaction of tumor cells with their microenvironment, 
making it difficult for the tumor cells to survive and eventually the inhibition of tumor growth10. As 
shown in the present study and reported earlier, endothelial cell types are more sensitive to TPT than 
tumor cell types (Fig.  2 and32). The sustained release of liposomally entrapped TPT was expected to 
simulate low dose metronomic chemotherapy. To investigate whether the metronomic dosing effect can 
be replicated in vitro, the responses of TES to a single dose of free TPT, liposomally entrapped TPT, and 
fractionated low doses of TPT in conjunction with radiation exposure were compared. TES were treated 
with free or entrapped TPT (250 nM) followed by radiation exposure after 6 hours. The culture media was 
replaced after 24 hours as described earlier for toxicity evaluation. For low dose metronomic treatment, 
the single dose of free TPT was fractionated into 3 or 5 doses given every 24 hours. Thus, the treatments 
consisted of 83 nM concentrations of free TPT every 24 hours for 3 days (3 fractions, 3 × 83 nM) or 
50 nM concentrations of TPT every 24 hours for 5 days (5 fractions, 5 × 50 nM) followed by subsequent 
replacement with fresh medium 24 hours after each treatment. At day10 the TES were imaged for siz-
ing, drug uptake and cell damage by confocal fluorescence microscopy. Decrease in TES size correlated 
with increased accumulation of TPT (green) and enhanced cell damage observed by PI staining (Red). 
The treatment results in TES that received fractionated dosing and radiation were comparable to those 
treated with the single dose of LTPT followed by radiation exposure (3 Gy) (Fig. 6A). Of the two free TPT 
metronomic treatment regimens, the 3 × 83 nM regimen was more effective than the 5 × 50 nM regimen 
(Fig. 6B). The results further suggest the relevance of an optimal in vitro model for preclinical evaluation 
of LDMC. Figure 7 provides a schematic comparing free, liposomal and metronomic dosing regimen of 
TPT in conjunction with radiation on TES at 10 days post treatment.
Enhanced cytotoxicity of LTPT with radiation results from differential intracellular phospho-
MAPK signaling in the endothelial component of the TES. A semi-quantitative comparison of 
the expression of 26 phosphoproteins involved in the stress and apoptotic signaling pathway in response 
to free TPT and LTPT at day 10 was performed by probing the Phospho-MAPK antibody arrays with 
TES lysates (Fig. 8A). ImageJ analyses of pixel intensities was used to identify the differential expression 
of phosphoproteins under different treatment conditions. The heat map generated (Fig.  8B) revealed 
a 2–5 fold increase in phosphorylation of JNK and p38 and ERK family of MAP kinases in the TES 
treated with LTPT and radiation. JNK and p38 are stress activated MAP kinases which are upregu-
lated in response to camptothecin derivatives like topotecan33,34 and radiation35,36. Sustained activation 
of ERK1/2, JNK or p38 plays a crucial role in the regulation of apoptosis, cell cycle progression, growth 
and differentiation37,38. JNK and p38 induce apoptosis by phosphorylating pro-apoptotic BAD39 and inac-
tivation of anti-apoptotic Bcl-2 and Bcl-xL proteins40.
Based on the different phosphoprotein expression trends in TES in response to various treatment 
conditions, they were grouped into two clusters (Figs 8B and 9). In cluster-1 consisting of 6 phosphop-
roteins, the three treatment groups including radiation alone and free or LTPT with radiation exhib-
ited a trend of increasing phosphorylation. However, the 8 phosphoproteins in cluster-2 appeared to be 
selectively upregulated in TES that were treated with LTPT and radiation (Fig. 9A). Of further interest 
was the phosphorylation of p53 at the serine 46 residue in cluster-1. Phosphorylation of the serine 46 
residue is critical to triggering the p53 dependent apoptotic signaling cascade found to occur in normal 
cell types41. Apoptotic stress resulting in phosphorylation of ERK, p38, and JNK has also been associated 
with phosphorylation and stabilization of the p53 tumor suppressor protein42. However, within TES, 
only the 2H11 endothelial cells that have a functional p53 that will undergo activation in response to an 
apoptotic or stress signal. The 4T1 murine mammary carcinoma cells are p53 null and do not express 
the p53 protein43. The Ingenuity pathway analysis (IPA) elucidated that the phosphorylation/activation of 
these proteins is associated with p53 (serine 46 residue) phosphorylation and impacts the amplification 
of apoptotic signals (Fig. 9B). The data suggests that the metronomic effect of the combined treatment 
of liposomal TPT and radiation on endothelial cells may be a possible reason for efficient activation of 
ERK, JNK and p38 family of MAP kinases resulting in enhanced toxicity observed at day 10 in the TES.
www.nature.com/scientificreports/
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Discussion
The typical treatment options available for TNBC are a combination of therapies such as surgery, 
chemotherapy and radiation44. Chemotherapy followed by radiotherapy has been shown to significantly 
increase the survival outcomes in TNBC women after mastectomy45. Metronomic oral topotecan alone 
or in combination with pazopanib has been shown to prolong survival and reduce metastasis in gastro-
intestinal and gynecological cancers5,46,47. Its use in LDMC has been limited in other types of cancers due 
in part to its short half-life of 3.5 hours in the circulation48 and the need for frequent administration47,49. 
Continuous infusion via intravenous administration not being a logical option owing to the patients 
inconvenience, has met with limited success and not yet become a standard practice in the clinic50,51. 
Efficiently loaded nanoparticles not only stabilize the therapeutic agents and influence the drug’s bio-
distribution52, but may also facilitate sustained release at the vascularized tumor site53,54. This sustained 
release in turn provides low concentration of active drug at the tumor site over a prolonged period of 
time, thus simulating the action of localized metronomic therapy in cancer16.
Figure 6. A single LTPT treatment results in TES toxicity levels that are comparable to the fractionated 
(metronomic) dosing regimen using free TPT in conjunction with radiation. The toxicity of repeated 
fractionated dosing was investigated against a single dose of free TPT or LTPT followed by a single exposure 
to radiation (3 Gy) in each treatment after the first dose. Fractionated regimens consisting of 3 × 83 nM 
or 5 × 50 nM TPT treatments with exchanges occurring each 24 hours were given and toxicity to TES was 
evaluated at day 10 post-treatment. (A) Fluorescence confocal images indicate greater uptake of PI (red) 
and accumulation of TPT (green) in the TES treated with repeated low concentrations of free TPT or the 
liposomal formulation in comparison to a single treatment of free TPT at a higher concentration (250 nM). 
Representative DIC images with decreases in the size of the TES confirm the associated cytoxicity in these 
treatment groups. (B) Quantitative analysis of spheroid size, TPT and PI intensity assessed at day 10 post-
treatment for the various treatment groups described indicates that the effect of the liposomal formulation 
was comparable to the fractionated dosing of free TPT. This is supported by the lack of significance in 
in TPT or PI uptake between LTPT and the metronomic TPT dosing. (n = 12 TES for spheroid size per 
treatment and n = 4 TES for PI staining and GFP expression) *P < 0.05; **P < 0.01.
www.nature.com/scientificreports/
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The rational use of antineoplastic agents in pharmacotherapy requires preclinical studies to model 
the pharmacokinetic/pharmacodynamics (PK/PD) for predicting the effect and efficacy of drug dosing 
over time. While the alternate paradigm of metronomic therapy is gaining pace when compared to the 
traditional paradigm of cytotoxic chemotherapy based on the MTD, there is still no accepted definition 
of the ‘metronomic dose’. Majority of the clinical trials administering metronomic therapy have utilized 
an arbitrary dose range of 10–33% of the MTD as the representative metronomic dose10,55. Therefore, 
to maximize the antitumor response, metronomic approaches have yet to optimize the drug schedule 
and dosage. In this respect cost-effective in vitro models, that allow for controlled experimental manip-
ulation, present a valuable predictive tool for optimization of dosing schedules before translation of the 
data to animals and clinical trials56. Advancing the efficacy of LDMC not only requires testing capable 
of determining the optimal dose but possible interaction of the formulation with other co-administered 
treatment modalities12,57. Current initiatives to address the specific issues of right dose, rhythm of drug 
administration and co-treatment modalities for LDMC utilize the novel approach of mathematical 
Figure 7. A schematic representation of free and liposomally entrapped TPT (LTPT) compared to 
the metronomic dosing regimen of free TPT studied in TES. Treatment response was determined 
by evaluating the changes in fluorescence intensity of TPT uptake, spheroid sizing of DIC (differential 
interference contrast) images, and propidium iodide (PI) staining of dead/damaged cells.
Figure 8. Phospho-MAP kinase expression profiling reveals elevated activation of proteins associated 
with stress and apoptotic signaling in TES treated with LTPT and radiation in comparison to a similar 
concentration of free TPT. (A) The human phosho-MAPK array was utilized to detect upregulation of 
several phosphoproteins in the TES spheroids treated with 250 nM LTPT or free TPT followed by radiation 
exposure of 3 Gy after 6 hours. TES subject to radiation exposure alone served as a control. Data shown 
are from a 60 second exposure of the array blot to x-ray film. (B) The graphs of pixel intensities (cluster 
1 and 2) representative of phosphoprotein expression profiles in TES upon treatment with free TPT and 
liposomally entrapped nanoformulation (LTPT) combined with radiation exposure.
www.nature.com/scientificreports/
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modeling of cancer growth58,59. A mathematical model based on the combined dynamics of the prolifer-
ating quiescent and necrotic tumor cells, endothelial cells and other normal cells along with the influence 
of the oxygen gradient and angiogenic factors was designed by Andre et. al to reproduce the expected 
efficacy of MTD and metronomic schedule for Temozolomide chemotherapy59. The usefulness of such 
mathematical models is in their versatility to adapt to several kinds of single or multi-agent therapeutic 
strategies. Multicellular tumor spheroids have served as ideal experimental model system for deriving 
the mathematical algorithms for cancer growth and associated therapy60–62. The 3D co-culture of tumor 
and endothelial cells in this study provides an improved system for the mathematical modeling of tumor 
and endothelial cell sensitivity to LDMC and determine the most effective drug/ therapeutic combination 
to translate to clinical settings.
In the current study we have developed a cost- effective tumor model for the screening and testing of 
metronomic and/or combinatorial therapeutic responses in vitro. The ability of the in vitro TES model to 
capture characteristics of the tumor microenvironment and continue to grow for several weeks in culture, 
unlike 2D monolayer cultures that need to be passaged in 3–4 days, enables analysis of the gradient of 
penetration/accumulation of drugs or nanoparticles over an extended period of time and provides a 
more predictive assessment of in vivo response. The 4T1 murine mammary carcinoma cells selected 
for co-culturing with the murine 2H11 endothelial cell line in this study exhibit growth and metastasis 
spread closely mimicking the human TNBC prognosis63. The 2H11 murine endothelial cell line isolated 
from the lymph nodes of adult C3H/He mice64 is very well characterized by the presence of features 
typical of normal endothelial cells and those of endothelial cells isolated directly from tumors65. These 
studies (Fig.  2) correlate with earlier reports that demonstrate that endothelial cells are more sensitive 
than tumor cells to TPT32 and radiation66,67. Recently redefined by Klement and Kamen, LDMC is the 
minimum biologically effective dose of a chemotherapeutic agent, which, when given at a continuous 
dosing regimen with no prolonged drug-free breaks leads to anti-tumor activity68 The antitumor activity 
of LDMC is due to increase in the sensitivity of proliferating endothelial cells in the tumor vasculature 
and inhibition of angiogenesis10,69. As demonstrated herein, sustained release of TPT from the liposomal 
formulation (LTPT) enhances TPT toxicity to the endothelial cells and provides similar efficacy in the 
TES model as metronomic therapy. Combined treatment with a single dose of LTPT and radiation also 
enhanced cytotoxicity and cell damage in the TES (Figs 4–7). Furthermore, semi-quantitative molecular 
studies using Phosho MAPK antibody arrays indicated that the enhanced TES cytotoxicity resulting 
from a combination of incubation with LTPT and radiation exposure is associated with the activation/ 
phosphorylation of p53 in endothelial cells as shown in Figs 8 and 9.
Efforts to evaluate complex combinations and novel cancer therapies have been challenging and 
require more representative yet cost-effective and reproducible in vitro models of human cancer. To 
evaluate metronomic therapy and radiation in preclinical in vitro models it is critical to have a more real-
istic representation of the tumor-endothelial cells, as both metronomic therapy and radiation function 
by affecting the tumor microenvironment. Further, the liposomal accumulation and drug release at the 
tumor site are extremely important for an understanding of the overall drug efficiency. Traditionally this 
Figure 9. The trend of phophoprotein expression and signaling network. (A) Based on the pixel densities 
of the signal in each spot of the array corresponding to the respective phosphorylated protein, they were 
grouped in one of the two clusters. (B) Ingenuity pathway analysis shows the interaction of phosphorylated 
proteins that are significantly activated in irradiated TES incubated in LTPT for 10 days. Interestingly 
activation of these proteins is associated directly or indirectly with the phosphorylation of functional p53 
(serine 46 residue) which is expected to be activated in endothelial cells only.
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information is obtained from in vivo studies in animal models. In vitro tumor models that can incorpo-
rate the principles of pharmacokinetics and pharmacodynamics (PK/PD) nanoparticle drug delivery to 
optimize therapeutic response may be considered the method of choice for optimizing the drug design 
prior to initiating expensive and resource-intensive experiments in animals56,70,71. The current studies 
demonstrate that a 3D TES model provides such representation of the tumor microenvironment by illus-
trating enhanced penetration and efficacy of liposomal formulations of TPT alone and in conjunction 
with a clinically-relevant dose of radiation.
Materials and Methods
Materials. Topotecan hydrochloride was purchased from AK Scientific (Union City, CA). Powders of 
1, 2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC), > 99%, and 1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (ammonium salt) (m-PEG DSPE), > 99% 
purity, were purchased from Avanti Polar Lipids (Alabaster, AL). Nuclepore® polycarbonate membranes 
(0.1 μ m), Dowex® 50WX8-200 resin in the H+ form, Sephadex® G-25 PD-10 columns, solvents, and 
buffer salts were purchased from Fisher Scientific (Florence, KY). All solvents were HPLC grade. MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was purchased from Sigma-Aldrich (St. 
Louis, MO), and cell culture media was obtained from GIBCO Life Technologies (Carlsbad, CA).
Actively-loaded Liposomal TPT Formulations. Large unilamellar liposomes containing 0.3 M 
ammonium besylate solutions were prepared as previously reported72,73. Briefly, DSPC and m-PEG-DSPE 
(95:5 molar ratio) were dissolved in chloroform. A thin lipid film was generated after evaporating CHCl3 
under N2 and fully dried under vacuum at 35 °C for 6 hours. Dried films were hydrated with 0.3 M 
ammonium besylate solutions made via ion exchange using Dowex® 50WX8–200 as reported previ-
ously24. The resulting suspensions were vortexed at 60 °C, then extruded through two, stacked 0.1 μ m 
polycarbonate membranes 10 times at 40 psig and 60 °C to yield ammonium besylate liposomes (ABLs) 
with a particle size (determined by dynamic light scattering) of 99.5 ± 3.5 nm and a polydispersity index 
of 0.13 ± 0.08 nm. Active loading of TPT into ABLs was performed by generating a low intravesicular 
pH via an ammonia gradient7. Extravesicular ammonia was removed to establish the gradient by passing 
0.6 mL of ABLs through a Sephadex® G-25 size exclusion column pre-equilibrated with pH 5.5 100 mM 
2-(N-morpholino)ethanesulfonic acid (MES) buffer. The first 2.5 mL fraction eluted from the column 
was discarded. The next 2.5 mL containing ABLs suspended in MES buffer was collected and 1.5 mL of 
the eluted suspension was mixed with an equal volume of TPT dissolved in the same pH 5.5 MES buffer 
to achieve a total extravesicular TPT concentration of 100 μ M and a lipid concentration of 1.86 mg/
mL. TPT active loading was performed for 1 hour at 60 °C with this suspension and achieved a loading 
efficiency of 72%. The resulting LTPT formulation was used for release studies after passing through a 
Sephadex-G25 column equilibrated with pH 7.4 phosphate buffer saline (PBS) or stored at 4 °C until 
needed.
Liposomal Characterization. Liposome particle size was analyzed by dynamic light scattering with 
the aid of a Beckman Delsa™ Nano C Particle Sizer (Brea, CA) as reported previously72. TPT suspensions 
collected during active loading or release studies were diluted with acidified methanol (0.001 N HCl) and 
stored at − 20 °C until analyses. Acidification converts TPT to its lactone form, which was later analyzed 
by HPLC72. Active drug loading and lipid composition of the liposomal formulations were determined 
as previously described74,75. Briefly, TPT lactone concentration was determined by HPLC using a Waters 
Symmetry C18 column (4.6 × 150 mm, 5 μ m) and a mobile phase (16% acetonitrile:84% (v/v) of 5% (pH 
5.5) triethylamine acetate buffer) at a flow rate of 1 mL/min. A fluorescence detector (M474) operating 
at excitation and emission wavelengths of 380 and 560 nm was used to monitor the lactone form of 
TPT, which exhibited a retention time of 4 min. A linear response was observed for TPT standards over 
the concentration range of 20–200 nM in acidified methanol. For lipid content determination, aliquots 
of liposome suspensions (100 – 250 μ L) were dried at room temperature under N2, then dissolved in 
chilled solvent (80% chloroform:19.5% methanol:0.5%(v/v) NH4OH). Lipid samples were analyzed using 
a Waters Alliance 2695 separation module and an Allsphere (Alltech Associates, Inc., Deerfield, IL) silica 
column (4 × 150 mm, 5 μ m) and guard column (20 × 4.0 mm, 5 μ m) and a mobile phase (80% metha-
nol:19.5% water:0.5% (v/v) NH4OH) at a flow rate of 1 mL/min. DSPC was quantified with this HPLC 
method using an evaporative light scattering detector (ELSD, Sedere, Inc., Lawrenceville, NJ) operated 
at 40 psig and 40 °C. DSPC standards (0.05 – 0.3 mg/mL) were dissolved in the same solvent as liposome 
samples. Plots of the logarithms of standard peak areas versus the logarithms of concentration were linear 
over this concentration range.
In-vitro release kinetics of liposomal TPT in PBS or culture medium at pH 7.4. A previously 
developed fluorescence method capable of determining the release kinetics of LTPT in PBS and plasma 
was used to monitor LTPT release in PBS and cell culture media in this study24. Briefly, 0.5 mL of LTPT 
suspension was passed through a Sephadex® G-25 column equilibrated with PBS or cell culture medium 
to remove unentrapped TPT resulting in suspensions of TPT-loaded liposomes in the release media of 
interest. The first 2.5 mL eluted from the column was discarded and the next 2.5 mL containing LTPT 
was collected and diluted four fold with PBS or cell culture medium. TPT release was monitored at 37 °C 
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using the red shift in TPT’s fluorescence excitation spectra that occurs as it is released72. Excitation spec-
tra (290–500 nm) were collected at an emission wavelength of 550 nm using a FluoroMax-3, Jobin Yvon 
Inc (Edison, NJ) operated at 37 °C, 0.5 s integration time, and 1.5 nm slit width. Free TPT concentration 
was determined by comparing the fluorescence intensity (excitation of 410 nm) of samples to TPT stand-
ards (0.2 μ M–5 μ M) in PBS or culture medium as described previously76. A 100 μ L aliquot of liposomal 
suspension was also dissolved in acidified Me OH and analyzed by HPLC to determine the total TPT 
suspension concentration at the beginning of each release study.
Cell lines and Culture. 4T1 is a highly metastatic murine mammary epithelial cell line, representa-
tive of the human triple negative breast cancer phenotype that does not express estrogen, progesterone 
and Her2 receptor77. Both 4T1 and green fluorescent protein expressing 4T1 (GFP-4T1) cell lines are 
used in this study. The 2H11 cell line validated as a tumor-like endothelial cell line by Walter-Yohrling 
et al.65 has attributes of both normal endothelial cells28 as well as endothelial cells directly isolated 
from tumors78. Tumor and endothelial cells were cultured in high-glucose Dulbecco’s modified Eagle’s 
medium supplemented with 5% fetal bovine serum, sodium pyruvate, non-essential amino acids, and 1% 
penicillin-streptomycin (Invitrogen, Carlsbad, CA) at 37 °C in a humidified atmosphere with 5% CO2.
X-Ray Irradiation. High energy radiation (X-Ray) exposure was given using the Varian TrueBeam 
System (Palo Alto, CA) at the Department of Radiation Medicine at the University of Kentucky. The 
instrument was set at a radiation dose rate of 1.018 ± 0.10 Gy/min at 150 kV and 6.6 mA. The standard 
radiation dose in all experiments was 3 Gy.
MTT assay. Cells were seeded at a density of 2 × 103 cells/well in 96-well plates and incubated at 37 °C 
for 24 hours. Cells were treated with nine different concentrations of TPT (0.075–5 μ M) with and with-
out radiation exposure. The radiation was applied 6 hours after TPT treatment. Seventy-two hours later, 
50 μ L of MTT (5 mg/mL in PBS) was added to each well and incubated at 37 °C for 4 hours followed by 
dimethylsulfoxide (DMSO) solubilization of the cells. The dissolved chromogen in DMSO was measured 
at an absorbance wavelength of 540 nm using a Spectramax microplate reader (Molecular Devices LLC, 
Sunnyvale, CA) at 37 °C. The percentage of viable cells was determined by comparison with untreated 
controls. The median inhibitory concentration or IC50 (i.e., 50% reduction in cell viability) was deter-
mined for both tumor and endothelial cell lines.
Clonogenic assay. One to five hundred cells were plated in 6-well culture plates and then treated 
with 1/2 and 1/4 the IC50 dose of TPT in triplicate. Cells were irradiated with 3 Gy of radiation 6 hours 
after drug treatment. After radiation exposure, plates were incubated at 37 °C and 5% CO2 for 10–12 
days until large colonies (> 1 mm) formed. The colonies were fixed and stained with 0.5% crystal violet 
(Sigma Aldrich, St. Louis, MO) in 50% methanol/water. Colonies were counted using ImageJ software 
and confirmed by manual counting.
Plating efficiency (PE) and survival fraction (SF) were calculated using following equations79:
= × % =
×
PE
number of colonies formed
number of cells seeded
SF
number of colonies in treatment group
number of cells seeded PE
100 ;
Survival fraction was determined for both tumor and endothelial cell lines after TPT treatment either 
in conjunction with or without radiation exposure. Survival fractions were calculated from n = 3 samples 
for each experiment.
3D “Hanging drop” co-cultures. Tumor-endothelial cell spheroids (TES) were generated by 
co-culturing 4T1 tumor cells and 2H11 endothelial cells in “hanging drops” of medium (Dulbecco mod-
ified Eagle medium with 10% fetal bovine serum and antibiotic mix) as previously described28. A single 
cell suspension of 4T1 cells and 2H11 cells (3000 cells/20 μ L) was dispensed on the inside of the lid of 
each well of a 48-well cell culture plate, Greiner CellStar (Kaysville, UT). Spheroids were grown as hang-
ing drops for 10 days and transferred to Greiner repellent plates when required for assessing treatment 
response. Spheroids composed of only GFP-4T1 cells were made with the same protocol.
Toxicity evaluation of Liposomal TPT in TES. Randomly selected equal-sized TES were treated 
with free TPT or the nanoliposomal suspension (LTPT). The selected drug treatment groups were irradi-
ated at 3 Gy after 6 hours. Drug containing media was replaced after 24 hours. Images for representation 
and quantitation of cell death, fluorescence and structural changes in the TES were obtained at day 10 
using an Olympus FV1000 laser scanning confocal microscope (Olympus America Inc. Melville, NY) 
and a Typhoon FLA 7000 (GE Healthcare, Piscataway, NJ). TES from all treatment groups were imaged 
for green fluorescent protein (GFP) in 4T1 cells and stained for propidium iodide (PI) to quantify the 
abundance of dead cells.
Scanning electron microscopy. 4T1 tumor cell and 4T1-2H11 tumor-endothelial cell spheroids 
grown in hanging drops for 10 days were transferred to Formvar/Carbon grids (Ted Pella Inc, Redding, 
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CA). The spheroid containing grids were imaged with an S-3200-N Hitachi scanning electron micro-
scope at an accelerating voltage of 16 kV to observe the spheroid compactness or integrity and extracel-
lular matrix formation.
Immunohistochemistry. Spheroids were harvested and frozen in Tissue-Tek® O.C.T., (Miles USA, 
Inc. Elkhart, IN). Eight μ m cryostat sections were obtained with a Leica CM1950 cryotome and trans-
ferred on to Superfrost™ Plus slides (Fischer Scientific, Boston, MA) for immunostaining. Slides were 
incubated in polyclonal rabbit anti-human fibronectin (Q0149, Dako) and collagen Type IV mouse mon-
oclonal antibodies for 30 min at room temperature followed by labelling using a Dako Envision + kit 
(IR630) from Dako North America Inc. (Carpinteria, CA) according to the manufacturer’s instructions. 
Signal was visualized with 3,3′ -Diaminobenzidine (DAB) followed by a light hematoxylin counterstain. 
Images were taken at 40X magnification using a Nikon Ti E upright microscope with a Cool SNAP HQ2 
CCD camera (Tokyo, Japan) and processed with NIS-Elements basic research software.
Hematoxylin and Eosin Staining and Imaging. Hematoxylin and eosin (H&E) staining was per-
formed by staining the cryostat sections of TES with Harris hematoxylin (aluminum potassium sulfate, 
hematoxylin, absolute alcohol, mercuric oxide, and glacial acetic acid) followed by 1% acid alcohol and, 
subsequently, 1% eosin. Images of spheroids were obtained as described above.
Microscopy and image analyses. TES fluorescence images were captured using a Olympus FV1000 
laser scanning confocal microscope (Olympus America Inc. Melville, NY) equipped with 10X and 20X 
objectives (NA = 1.32). Two channels were acquired sequentially with the following excitation and emis-
sion parameters: 405 and 465–500 nm for accumulation of TPT or GFP expression in tumor cells and 
543 and 555–615 nm for PI staining of dead cells. The monochromatic differential interference contrast 
(DIC) images provided assessment of TES morphology and size. Gains were adjusted to avoid saturation 
in pixel intensity. Each TES image consisted of 24 optical images separated by 5 μ m along the z-axis cap-
tured at a 512 × 512 resolution and a speed of 10 μ s/pixel for both channels. A DIC image was acquired 
after each Z-stack image for accurate sizing. All 24 optical slices were collapsed to generate a maximum 
(i.e. cumulative) intensity projection image with the FV10-ASW 1.7 image processing software. TPT/
GFP or PI staining was quantified using an Olympus image analysis or ImageJ 1.47v (NIH, Bethesda, 
USA) software.
Phospho MAPK Antibody Array. TES harvested 10 days post-treatment were homogenized using a 
21-gauge syringe in lysis buffer as described earlier28. Insoluble material were removed by centrifugation 
(15 min, 12000 g). The protein concentration was determined using micro BCA protein assay kit (Thermo 
scientific Pierce, Rockford, IL). 125 μ g of lysate was hybridized to a human phospho MAPK antibody 
array (R&D Systems Inc, Minneapolis, MN) as instructed.
Pathway Analysis. The Ingenuity Pathway Analysis Tool was used to identify gene networks and 
examine the functional associations between differentially expressed proteins in the MAPK arrays 
obtained from incubation with lysates of TES following treatment (www.ingenuity.com).
Statistical analyses. Data are expressed as mean ± SD of at least three different experiments unless 
otherwise mentioned. Cell survival, sizing, and PI/GFP data for TES were represented as means (N = 4–12 
TES per group) ± SD. Statistical analyses were performed using Graphpad Prism software version 5.04 
(GraphPad.com). Two tailed unpaired t-tests with Welch’s correction was used to determine statistical 
significance. The level of significance was accepted at p < 0.05. For analysis of data from the Phospho 
MAPK antibody arrays, K-means clustering in conjunction with correlation metric was used to partition 
the markers into two clusters based on their expression profile across the three conditions corresponding 
to the following treatments: radiation (3 Gy), 3 Gy + TPT and 3 Gy + LTPT.
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